Overview

* Tango Q2 2025 collaboration revenue declines compared to same period last year

* Company reports net loss of $38.9 mln, EPS of $0.35 for Q2 2025

* Tango advancing TNG462 and TNG456 trials, data expected later this year

Outlook

* Company expects TNG462 clinical data update in 2H 2025

* Tango anticipates cash reserves to fund operations into Q1 2027

* Company plans registrational trial for TNG462 in pancreatic cancer next year

* Tango expects TNG260 clinical data presentation in 2H 2025

Result Drivers

* COST MANAGEMENT - Reduced R&D expenses due to decreased spending on discontinued programs, offset by increased investment in TNG462, TNG456, and TNG961

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $3.18

Collabor mln

ation

Revenue

Q2 EPS -$0.35

Q2 Net -$38.85

Income mln

Q2 Basic -$0.35

EPS

Q2 $44.15

Operatin mln

g

Expenses

Q2 -$40.97

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Tango Therapeutics Inc ( TNGX ) is $9.50, about 30.6% above its August 4 closing price of $6.59

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)